Device company Nemera has announced that it will develop devices for the delivery of inhaled nanoparticles for the treatment of cardiovascular disease as part of the Cupido (Cardio Ultraefficient Nanoparticles For Inhalation Of Drug Products) consortium.
The Cupido project, funded by the €6 million from the EU Horizon 2020 Framework Program, has set as its goal, “to hit the core of the cardiovascular disease, developing inhalable nanoparticles that can deliver a therapy directly to the diseased heart.”
Other participants in the 12-member consortium include Sanofi, Plumestars, and Imperial College London.
Nemera CEO Marc Haemel commented, “There is no limit to Nemera’s ambition to serve patients. We already market devices in over 40 countries for millions of users. We’ll keep investing in new products and in state-of-the-art manufacturing equipment, to help even more patients with high quality devices all over the world.”
